FinancialNewsMedia.com News Alert: Opiate-induced severe abdominal pain leads to escalating dosages and drug dependence – LOS ANGELES, CA – (http://www.financialnewsmedia.com News Alert) – Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it is advancing its cannabosides pharmaceuticals for treatment of narcotic bowel syndrome, a severe form of opiate-induced abdominal pain.
Every day more than 650,000 opioid prescriptions are dispensed by US pharmacies, resulting in over 200 million opioid prescriptions dispensed annually. Studies have reported that up to 81% of patients treated with opiates have functional bowel disorders, but these common symptoms may lead to underdiagnosis of opiate-induced severe abdominal pain. More than half (58%) of opiate users have reported chronic abdominal pain in independently-conducted clinical studies, and narcotic bowel syndrome is the most severe form of this disorder, where abdominal pain paradoxically increases despite continued administration of narcotics to treat the pain. When undiagnosed, patients or physicians continue to escalate dosages, which temporarily relieves pain, but leads to addiction and also worsens the abdominal pain — a vicious cycle. Narcotic bowel syndrome has dire consequences for opiate users, as their quality-of-life has been reported to be worse than patients with quadriplegia.
The clinical use of cannabinoids for resolving pain and inflammation is well established, including in large (n=313) independently-conducted clinical studies of inflammatory bowel disease, where 84% of patients reported an improvement in abdominal pain. Vitality’s proprietary cannabosides enable the selective delivery of cannabinoids to the intestinal tract, enabling large concentrations of THC and CBD (delta9-tetrahydrocannabinol and cannabidiol, respectively) to be delivered without any resulting psychoactivity. Read this and more news for VBIO at: http://financialnewsmedia.com/profiles/vbio.html
“In the midst of an opiate epidemic, with no simple solution in sight, we’re developing a truly…